Acadia Pharmaceutica (ACAD)

Feb 14, 2025, 4:05 PM EST - 8 days ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 12, 2025, 4:05 PM EST - 10 days ago

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Jan 14, 2025, 9:05 AM EST - 5 weeks ago

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

Jan 14, 2025, 9:00 AM EST - 5 weeks ago

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome

Dec 19, 2024, 4:05 PM EST - 2 months ago

Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

Dec 11, 2024, 4:05 PM EST - 2 months ago

Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Dec 9, 2024, 9:00 AM EST - 2 months ago

Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer

Nov 27, 2024, 3:18 PM EST - 3 months ago

Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET

Nov 26, 2024, 4:05 PM EST - 3 months ago

Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711

Nov 21, 2024, 4:05 PM EST - 3 months ago

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Nov 11, 2024, 10:50 AM EST - 3 months ago

Acadia Pharmaceuticals: Proving The Naysayers Wrong

Nov 6, 2024, 8:09 PM EST - 3 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call Transcript

Nov 6, 2024, 4:05 PM EST - 3 months ago

Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview

Nov 5, 2024, 4:05 PM EST - 3 months ago

Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Oct 17, 2024, 6:41 PM EDT - 4 months ago

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024

Oct 16, 2024, 4:07 PM EDT - 4 months ago

Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome

Sep 23, 2024, 4:15 PM EDT - 5 months ago

Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals

Sep 19, 2024, 12:00 PM EDT - 5 months ago

Axcelead Drug Discovery Partners Enters into Master Service Agreement for Drug Discovery Projects with Acadia Pharmaceuticals

Aug 26, 2024, 3:02 PM EDT - 6 months ago

Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again

Aug 14, 2024, 8:04 AM EDT - 6 months ago

Ryan Reynolds Announces More to Parkinson's® Campaign

Aug 7, 2024, 4:30 PM EDT - 7 months ago

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference

Aug 6, 2024, 10:15 PM EDT - 7 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:05 PM EDT - 7 months ago

Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview

Jul 24, 2024, 4:05 PM EDT - 7 months ago

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024

Jul 18, 2024, 9:04 AM EDT - 7 months ago

Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med

Jun 23, 2024, 11:32 AM EDT - 8 months ago

Acadia Pharmaceuticals: Back In The Buy Zone

Jun 18, 2024, 9:04 AM EDT - 8 months ago

Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting

Jun 18, 2024, 9:00 AM EDT - 8 months ago

New Millie Report Finds Hybrid Maternal Healthcare Model Improve Deliveries, Patient Engagement and Cost Savings

ALLG

Jun 5, 2024, 11:46 PM EDT - 9 months ago

Acadia Pharmaceuticals: Bullish On Nuplazid And Daybue Driven Growth In CNS Treatments

May 15, 2024, 9:05 AM EDT - 10 months ago

Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome

May 8, 2024, 9:00 PM EDT - 10 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:05 PM EDT - 10 months ago

Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview

Apr 29, 2024, 4:16 PM EDT - 10 months ago

Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship

Apr 24, 2024, 4:05 PM EDT - 10 months ago

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024

Apr 22, 2024, 9:04 AM EDT - 10 months ago

Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada

Apr 17, 2024, 4:05 PM EDT - 11 months ago

Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting

Apr 2, 2024, 4:05 PM EDT - 11 months ago

Acadia Appoints Elizabeth H. Z. Thompson, Ph.D.

Apr 1, 2024, 4:05 PM EDT - 11 months ago

Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 13, 2024, 4:05 PM EDT - 1 year ago

Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day

Mar 13, 2024, 9:23 AM EDT - 1 year ago

Evaluating Acadia's Market Position Following Pimavanserin's Clinical Setback

Mar 12, 2024, 5:45 PM EDT - 1 year ago

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm

Mar 12, 2024, 3:20 PM EDT - 1 year ago

Acadia Pharmaceuticals Stock Sinks After Schizophrenia Drug Study Falls Short

Mar 11, 2024, 5:01 PM EDT - 1 year ago

Acadia Pharma's stock falls 15% after failed drug trial